Nakayama Yui, Morimoto Satoru, Yoneda Misao, Kuzuhara Shigeki, Kokubo Yasumasa
Medical Department, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
Department of Neurology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaemachi, Itabashi-ku, Tokyo 173-0015, Japan.
J Neurodegener Dis. 2013;2013:679089. doi: 10.1155/2013/679089. Epub 2013 Mar 27.
Objective. Amyotrophic lateral sclerosis/parkinsonism-dementia complex is classified as one of the tauopathies. Methods. The total tau, phosphorylated tau, and amyloid β42 levels were assayed in cerebrospinal fluid from patients with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex (n = 12), Alzheimer's disease (n = 9), Parkinson's disease (n = 9), amyotrophic lateral sclerosis (n = 11), and controls (n = 5) using specific enzyme-linked immunosorbent assay methods. Results. Total tau and phosphorylated tau did not increase and amyloid β42 was relatively reduced in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Relatively reduced amyloid β42 might discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from amyotrophic lateral sclerosis and Parkinson's disease, and the ratios of phosphorylated-tau to amyloid β42 could discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer's disease. Conclusions. Cerebrospinal fluid analysis may be useful to differentiate amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease.
目的。肌萎缩侧索硬化症/帕金森病-痴呆综合征被归类为tau蛋白病之一。方法。使用特异性酶联免疫吸附测定法，对木曾肌萎缩侧索硬化症/帕金森病-痴呆综合征患者（n = 12）、阿尔茨海默病患者（n = 9）、帕金森病患者（n = 9）、肌萎缩侧索硬化症患者（n = 11）及对照者（n = 5）的脑脊液中的总tau蛋白、磷酸化tau蛋白及淀粉样β42水平进行检测。结果。木曾肌萎缩侧索硬化症/帕金森病-痴呆综合征患者的总tau蛋白和磷酸化tau蛋白未升高，淀粉样β42相对降低。淀粉样β42的相对降低可能有助于将木曾肌萎缩侧索硬化症/帕金森病-痴呆综合征与肌萎缩侧索硬化症和帕金森病区分开来，磷酸化tau蛋白与淀粉样β42的比值可将木曾肌萎缩侧索硬化症/帕金森病-痴呆综合征与阿尔茨海默病区分开来。结论。脑脊液分析可能有助于区分肌萎缩侧索硬化症/帕金森病-痴呆综合征与阿尔茨海默病、肌萎缩侧索硬化症和帕金森病。
